psalexa
P&S Market Research - A market research firm

Choroidal Neovascularization Market

Global Choroidal Neovascularization (CNV) Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10048
Available Format:

Choroidal neovascular are the new blood vessels that grow just below the retina and interrupt the vision. Choroid, which is responsible for oxygen and nutrients supply to the eye, is the area between the retina and the sclera, where the blood vessels grow and cause choroidal neovascularization (CNV). Choroidal neovascularization break the barrier between retina and choroid and the membrane leaks in the retina causing vision loss. Choroidal neovascularization leads to various severe eye diseases such as histoplasmosis, eye trauma, wet age related macular degeneration and myopic macular degeneration. Myopic macular degeneration is generally found in aged people because of tremendous elongation of their eyeball, leading to loss of vision in them. Mostly, the causes for choroidal neovascular are idiopathic, infections, choroidal tumors, degeneration, and trauma.

Ophthalmology is the branch of medical science that deals with the study and management of physiology, anatomy and the diseases related to human eye. The vision loss and incidence of eye disorders are becoming a major public health issues. The various eye diseases are glaucoma, age-related macular degeneration, cataract, diabetic macular edema, retinal detachment, ocular hypertension, bulging eyes, refractive errors and uveitis. The drugs in the market for choroidal neovascularization are lucentis and macugen, approved for CNV associated with wet AMD, and visudyne, approved for CNV associated with pathologic myopia and presumed ocular histoplasmosis. An Avastin drug is also available which is used as an off-label drug for choroidal neovascularization.

Innovation of products with the focus on enhanced efficiency, and growing demographics and economies in the emerging countries such as China and India are some of the major opportunities for choroidal neovascularization market. Increasing prevalence of choroidal neovascularization cases, high patient and physician satisfaction, increasing aging population and rising government initiatives towards healthcare infrastructure in the developing countries are some of the major factors that are driving the growth of global choroidal neovascularization market. Additionally, increase incidences of lifestyle associated diseases such as high blood pressure and diabetes are also acting as a driver for the growth of global choroidal neovascularization (CNV) market.

Some of the major factors restraining the growth of global choroidal neovascularization market are lack of awareness among people about different types of eye diseases, high cost concerned with the treatment, lack of access to primary healthcare services in developing countries, absence of health insurance and poor primary healthcare infrastructure. Also, rising healthcare cost in developing countries, such as China and India, is also hindering the affordability of healthcare facilities for the aging population.

North America had the largest choroidal neovascularization (CNV) market in 2014, attributed to growing population of baby boomers and increasing incidences of choroidal diseases in the region. The Asia-Pacific choroidal neovascularization market is growing with the highest rate compared to the market in other regions. China and India are the two countries, in Asia-Pacific, witnessing fastest growth of choroidal neovascularization markets. Large population of these countries coupled with raising government initiatives and support are the major driving factors of choroidal neovascularization markets in this region.

Some of the major competitors in choroidal neovascularization CNV market are Bayer AG, Chengdu Kanghong Biotech Co. Ltd., Resolvyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., , Valeant Pharmaceuticals International Inc., Promedior Inc., Mat Biopharma SAS, Quark Pharmaceuticals Inc., Novartis AG, and Gilead Sciences Inc.

Report Coverage

  • Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
  • Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
  • Uncovers potential demands in the market
  • Porter analysis identifies competitive forces within the market
  • Provides information on the historical and current market size and the future potential of the market
  • Provides sizes of key regional markets using yardsticks of processes, segments, products, end user and technology, etc (as applicable)
  • Highlights the competitive scenario of the market, major competitors, market share, benchmarking, investments and merger acquisitions
  • Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.

 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry